SCHEMBL1928299

SCHEMBL1928299

CN1CCC(OS(C)(=O)=O)C1

nearest known ligand 0.42

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
CYP2D6 P10635 1/20 0.37
HRH3 Q9Y5N1 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108992 1.00 CHRM4 (0.38) CHRM4CHRM5CHRM1CHRM3CYP2D6
SCHEMBL23175194 0.88 SMN1; SMN2 (0.46) CHRM1CHRM3CYP2D6SMN1; SMN2ALDH1A1
SCHEMBL3749371 0.88 SMN1; SMN2 (0.46) CHRM1CHRM3CYP2D6SMN1; SMN2ALDH1A1
SCHEMBL1928295 0.87 CYP2D6 (0.46) CHRM4CHRM5CHRM1CHRM3CYP2D6
SCHEMBL16382667 0.82 CHRM4 (0.32) CHRM4CHRM3HRH3
SCHEMBL8487018 0.78 HRH3 (0.32) HRH3
SCHEMBL8540595 0.78 TP53 (0.42) CYP2D6HRH3SMN1; SMN2ALDH1A1
SCHEMBL9918150 0.78 HRH3 (0.32) HRH3
SCHEMBL8540599 0.78 TP53 (0.42) CYP2D6HRH3SMN1; SMN2ALDH1A1
SCHEMBL8540600 0.78 TP53 (0.42) CYP2D6HRH3SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724431-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND USE THEREOF Beone Medicines I GmbH (CH) 2026-04-15 EP disclosed
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2026-03-26 US disclosed
US-20240239790-A1 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor LIFEARC (GB) 2024-07-18 US disclosed
CN-117693505-A Heteroaryl derivative compounds and uses thereof 沃若诺伊公司 2024-03-12 CN disclosed
EP-3632907-B1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2024-02-28 EP disclosed
EP-3632907-B1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2024-02-28 EP disclosed
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2024-01-18 US disclosed
EP-4305032-A1 7-MORPHOLINO-1,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR Admare Therapeutics Society (CA) 2024-01-17 EP disclosed
CN-116568675-A Cyclic isothiourea derivatives as CXCR4 modulators 埃尔米乌治疗公司 2023-08-08 CN disclosed
EP-4217353-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS Ermium Therapeutics (FR) 2023-08-02 EP disclosed
EP-0946539-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1999-10-06 EP disclosed
WO-1998027081-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1998-06-25 WO disclosed
US-5109013-A 2-(2-substituted aminoethyl)-1,4-dialkyl-3,4-dihydro-1H-1,3,5]triazepino[3,2-a]benzimidazol-5(2H)-ones as muscle relaxants A. H. ROBINS COMPANY, INCORPORATED (US) 1992-04-28 US disclosed
US-4812565-A ANTIHISTAMINE INTERMEDIATES A. H. ROBINS COMPANY, INCORPORATED (US) 1989-03-14 US disclosed
US-4810795-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1989-03-07 US disclosed
US-4727152-A Intermediates useful in the preparation of fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof A. H. ROBINS COMPANY, INC. (US) 1988-02-23 US disclosed
US-4705853-A ANTIHISTAMINES A. H. ROBINS COMPANY, INC. (US) 1987-11-10 US disclosed
US-4642343-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1987-02-10 US disclosed
US-4604388-A Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof in a method of counteracting histamine A. H. ROBINS COMPANY, INCORPORATED (US) 1986-08-05 US disclosed
US-4592866-A Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof A. H. ROBINS COMPANY, INC. (US) 1986-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239790-A1 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor DCK, ERCC2, POLK CHRM4 4872/4885CHRM5 4818/4885CHRM1 4863/4885
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF SIK1, CHUK, SIK2 CHRM4 2874/4885CHRM5 1375/4885CHRM1 2232/4885
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS CXCR4, CXCR1, CXCL12 CHRM4 1881/4885CHRM5 2748/4885CHRM1 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.